The Proposed European Approach to BOLAR: An Appropriate Adaptation of the Experimental Use Exemption for the European Community?

By Dr Manja Epping, Lawyer at Ashurst and Ina Gerstberger, Lawyer at Taylor Wessing

Dr Manja Epping is a qualified lawyer working in the Munich office of international law firm Ashurst. In 1990 she took a French degree (Maоtrise en droit) in international and European law. After having qualified in Germany in 1995, Manja wrote her doctoral thesis on German and international arbitration law. Since then, she has specialised in German and European intellectual property law including regulatory issues, with a particular focus on the pharmaceutical and nutraceutical industries. She is an experienced litigator and a regular speaker at conferences.


Ina Gerstberger studied Biochemistry and Law and worked as a Research Assistant at the Department of Public Law at the University of Hannover. She is now a qualified Lawyer at the Munich office of the international full-service law firm Taylor Wessing. Ina specialises in pharmaceuticals, chemistry and biotechnology patent matters and the protection of plant varieties. She also advises clients on R&D and licensing contracts. Ina has particular expertise in delimitation of pharmaceuticals, foodstuffs, medical devices and the approval of biocides, as well as unfair competition law in relation to medicinal products. She is a regular speaker at conferences.